Type 2 diabetes mellitus (T2DM) is a major public health problem. However, few clinicians screen routinely to detect this problem early or manage hyperglycaemia aggressively if it is found. As even transient normalization of glucose levels in prediabetes reduces the risk of developing T2DM, these practices should change.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Perreault, L. et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379, 2243–2251 (2012).
Butler, A. E. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110 (2003).
Weyer, C., Bogardus, C., Mott, D. M. & Pratley, R. E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104, 787–794 (1999).
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med 346, 393–403 (2002).
Colagiuri, S., Cull, C. A., Holman, R. R. & UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diab. Care 25, 1410–1417 (2002).
[No authors listed] Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128, 517–523 (1998).
Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412 (2000).
Phillips, L. S. et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetol. 52, 1798–1807 (2009).
The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1203858.
Gong, Q. et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetol. 54, 300–307 (2011).
Acknowledgements
The views expressed are those of the authors and do not represent those of the U.S. Department of Veterans Affairs or Emory University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L. S. Phillips and D. E. Olson have declared associations with the following companies/organizations: Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, Roche and Sanofi (grant/research support), Boehringer Ingelheim and Janssen Pharmaceuticals (scientific advisory boards).
Rights and permissions
About this article
Cite this article
Phillips, L., Olson, D. Normal glucose levels should be the goal. Nat Rev Endocrinol 8, 510–512 (2012). https://doi.org/10.1038/nrendo.2012.139
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.139